Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is -9.67% lower on its value in year-to-date trading and has touched a low of $202.57 and a high of $306.08 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The VRTX stock was last observed hovering at around $215.53 in the last trading session, with the day’s loss setting it -2.05% off its average median price target of $279.50 for the next 12 months. It is also 38.48% off the consensus price target high of $347.00 offered by 26 analysts, but current levels are 14.61% higher than the price target low of $250.00 for the same period.
Currently trading at $213.48, the stock is -1.18% and -0.53% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.42 million and changing -0.95% at the moment leaves the stock -10.26% off its SMA200. VRTX registered -16.92% loss for a year compared to 6-month gain of 3.06%. The firm has a 50-day simple moving average (SMA 50) of $215.80 and a 200-day simple moving average (SMA200) of $221.37.
The stock witnessed a -1.49% loss in the last 1 month and extending the period to 3 months gives it a -5.23%, and is -2.86% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.67% over the week and 1.83% over the month.
Vertex Pharmaceuticals Incorporated (VRTX) has around 3400 employees, a market worth around $54.77B and $6.21B in sales. Current P/E ratio is 20.72 and Fwd P/E is 16.36. Profit margin for the company is 43.70%. Distance from 52-week low is 5.39% and -30.25% from its 52-week high. The company has generated returns on investments over the last 12 months (26.40%).
Vertex Pharmaceuticals Incorporated (VRTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Vertex Pharmaceuticals Incorporated (VRTX) is a “Buy”. 26 analysts offering their recommendations for the stock have an average rating of 1.80, where 4 rate it as a Hold and 3 think it is a “Overweight”. 19 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Vertex Pharmaceuticals Incorporated is expected to release its quarterly report on 07/28/2021 and quarterly earnings per share for the current quarter are estimated at $2.69 with sales reaching $1.66B over the same period.The EPS is expected to grow by 128.00% this year, but quarterly earnings will post 11.90% year-over-year. Quarterly sales are estimated to grow 9.40% in year-over-year returns.
Vertex Pharmaceuticals Incorporated (VRTX) Top Institutional Holders
1,430 institutions hold shares in Vertex Pharmaceuticals Incorporated (VRTX), with 353.55k shares held by insiders accounting for 0.14% while institutional investors hold 95.16% of the company’s shares. The shares outstanding are 258.43M, and float is at 258.30M with Short Float at 1.89%. Institutions hold 95.03% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 24.27 million shares valued at $5.74 billion. The investor’s holdings represent 9.38% of the VRTX Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 20.43 million shares valued at $4.83 billion to account for 7.89% of the shares outstanding. The other top investors are Price (T.Rowe) Associates Inc which holds 19.63 million shares representing 7.58% and valued at over $4.64 billion, while FMR, LLC holds 5.08% of the shares totaling 13.14 million with a market value of $3.11 billion.
Vertex Pharmaceuticals Incorporated (VRTX) Insider Activity
A total of 169 insider transactions have happened at Vertex Pharmaceuticals Incorporated (VRTX) in the last six months, with sales accounting for 131 and purchases happening 38 times. The most recent transaction is an insider sale by Sanna Bastiano, the company’s EVP, Cell & Genetic Therapies. SEC filings show that Sanna Bastiano sold 1,686 shares of the company’s common stock on Apr 05 at a price of $214.14 per share for a total of $0.36 million. Following the sale, the insider now owns 35834.0 shares.
Vertex Pharmaceuticals Incorporated disclosed in a document filed with the SEC on Mar 05 that Liu Joy (SVP, General Counsel) sold a total of 5,141 shares of the company’s common stock. The trade occurred on Mar 05 and was made at $209.69 per share for $1.08 million. Following the transaction, the insider now directly holds 8253.0 shares of the VRTX stock.
Still, SEC filings show that on Mar 01, Silva Paul M (SVP & Chief Accounting Officer) disposed off 2,782 shares at an average price of $211.45 for $0.59 million. The insider now directly holds 9,884 shares of Vertex Pharmaceuticals Incorporated (VRTX).
Vertex Pharmaceuticals Incorporated (VRTX): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 7.00% up over the past 12 months. Bristol-Myers Squibb Company (BMY) is 6.26% up on the 1-year trading charts. Short interest in the company’s stock has risen 1.81% from the last report on Apr 14, 2021 to stand at a total of 4.89 million short shares sold with a short interest ratio of 2.81.